Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Bridging Study of Adomeglivant Formulations
NCT02385084Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adomeglivant in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity and Maximum Plasma Concentration. Started Mar 2015; status: terminated.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02385084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385084.